The aim of this study was to explore the immediate adaptive response to EGFR-TKIs and to suggest novel relevant targets for EGFR-TKI based combination therapy for improved treatment of NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.